• English
    • français
  • Help
  •  | 
  • Contact
  •  | 
  • About
  •  | 
  • Login
  • HAL portal
  •  | 
  • Pages Pro
  • EN
  •  / 
  • FR
View Item 
  •   LillOA Home
  • Liste des unités
  • Lille Neurosciences & Cognition (LilNCog) - U 1172
  • View Item
  •   LillOA Home
  • Liste des unités
  • Lille Neurosciences & Cognition (LilNCog) - U 1172
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Traitements medical et chirurgical de la ...
  • BibTeX
  • CSV
  • Excel
  • RIS

Document type :
Article dans une revue scientifique: Article original
DOI :
10.1016/j.lpm.2017.01.018
PMID :
28279509
Permalink :
http://hdl.handle.net/20.500.12210/15826
Title :
Traitements medical et chirurgical de la maladie de parkinson
Author(s) :
DEFEBVRE, Luc [Auteur] refId
Troubles cognitifs dégénératifs et vasculaires - U1171
Troubles cognitifs dégénératifs et vasculaires - U 1171 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U 1171 [TCDV]
moreau, caroline [Auteur] refId
Troubles cognitifs dégénératifs et vasculaires - U1171
Troubles cognitifs dégénératifs et vasculaires - U 1171 [TCDV]
Journal title :
Presse medicale (Paris, France . 1983)
Abbreviated title :
Presse Med.
Volume number :
46
Pages :
218-224
Publication date :
2017-03-01
ISSN :
0755-4982
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
The treatment of Parkinson's disease is symptomatic with the use of dopaminergic medications: levodopa, dopaminergic agonists and enzymatic inhibitors. At the initial stage, the main goals are to improve the quality of ...
Show more >
The treatment of Parkinson's disease is symptomatic with the use of dopaminergic medications: levodopa, dopaminergic agonists and enzymatic inhibitors. At the initial stage, the main goals are to improve the quality of life of patients and delay the onset of motor complications, using a combination of these therapies taking into account both clinical disability and tolerance of different treatments. At the stage of motor and non-motor fluctuations inhibitors of MAO-B and COMT are proposed; amantadine may limit moderate dyskinesias. At the stage of disabling fluctuations continuous dopaminergic strategy is discussed: deep brain stimulation of different targets, subcutaneous apomorphine pump and intra intestinal Duodopa®Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
CNRS
Inserm
Université de Lille
Collections :
  • Lille Neurosciences & Cognition (LilNCog) - U 1172
Research team(s) :
Troubles cognitifs dégénératifs et vasculaires
Submission date :
2019-11-27T13:01:37Z
Université de Lille

Mentions légales
Université de Lille © 2017